n-(4-hydroxyphenyl)all-trans retinamide
Small moleculeexperimental
Clinical trial activity
42 trials · 38 clinical orgs · 0 marketing orgs
Phase 1
18
Phase 2
23
Phase 3
5
Phase 4
0
Earliest trial started Sep 1, 1992 (NCT00003075)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 3
- Burkitt Lymphoma · Phase 1/Phase 2
- Cognition · Phase 3
- Cystic Fibrosis · Phase 1
- Geographic Atrophy · Phase 2
- Glioblastoma · Phase 2
- Gliosarcoma · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Insulin Resistance · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 2
- Macular Degeneration · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 3
- Neuroblastoma · Phase 2
- Obesity · Phase 2
- Ovarian Neoplasms · Phase 2
- Precancerous Conditions · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms · Phase 2
- Psychotic Disorders · Phase 3
- Schizophrenia · Phase 3
- Urinary Bladder Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Waldenstrom Macroglobulinemia · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1- Mol. weight
- 391.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL7301 ↗
Also known as
- 4-hpr
- 4-hpr
- 4-hpr
- 4-hydroxy(phenyl)retinamide
- 4-hydroxy(phenyl)retinamide
- fenretinide
- fenretinide
- fenretinide
- fenretinide
- fenretinidev
- mcn-r-1967
- mcn-r-1967
- n-(4-hydroxyphenyl)all-trans retinamide
- n-(4-hydroxyphenyl)all-trans retinamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01553071 | Phase 1 | Nov 1, 2016 | South Plains Oncology Consortium |
| NCT02495415 | Phase 2 | Jan 1, 2016 | CerRx, Inc. |
| NCT02163356 | Phase 1 | May 1, 2014 | EVAN Foundation, South Plains Oncology Consortium, The University of Texas, Dallas |
| NCT02141958 | Phase 1 | Apr 1, 2014 | McGill University |
| NCT02075177 | N/A | Feb 27, 2014 | South Plains Oncology Consortium |
| NCT01535157 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | South Plains Oncology Consortium, Texas Tech University, The University of Texas, Dallas |
| NCT01187810 | Phase 1 | Aug 1, 2010 | South Plains Oncology Consortium, Texas Tech University, University of Texas at Houston |
| NCT01479192 | Phase 3 | Dec 1, 2009 | University of Milan |
| NCT00546455 | Phase 2 | Dec 1, 2007 | University of California, San Diego |
| NCT00534898 | Phase 3 | Sep 24, 2007 | Ben Gurion University |
| NCT00589381 | Phase 1 | Aug 1, 2007 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00429936 | Phase 2 | Dec 1, 2006 | ReVision Therapeutics, Inc., Sirion Therapeutics |
| NCT00646230 | Phase 1 | Dec 1, 2006 | NantWorks, National Cancer Institute (NCI), Texas Tech University, University of Southern California |
| NCT00387504 | Phase 1 | Nov 1, 2006 | National Cancer Institute (NCI), University of California, Berkeley, University of Southern California |
| NCT00295919 | Phase 1 | Dec 1, 2005 | National Cancer Institute (NCI), Texas Tech University, University of Southern California |
| NCT00288067 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | National Cancer Institute (NCI), University of Washington |
| NCT00104923 | Phase 1 | Feb 1, 2005 | National Cancer Institute (NCI), University of California, Berkeley, University of Southern California |
| NCT00103090 | Phase 1 | Jan 1, 2005 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00102635 | Phase 1 | Jan 1, 2005 | National Cancer Institute (NCI), Schering-Plough, University of Texas at Houston |
| NCT00098800 | N/A | Oct 1, 2004 | National Cancer Institute (NCI), University of Arizona |
Showing 20 of 42 trials
Page 1 / 3
Organizations
Research & Development (38)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 31 | 9 | 4 | 1992 |
| University of Texas at Houston | Academic/Hospital | 9 | 6 | 3 | 1992 |
| University of Southern California | Academic/Hospital | 7 | 1 | 2 | 1998 |
| South Plains Oncology Consortium | Academic/Hospital | 5 | 5 | 3 | 2010 |
| Texas Tech University | Academic/Hospital | 4 | 0 | 2 | 2005 |
| Wayne State University | Academic/Hospital | 3 | 2 | 2 | 1997 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 2 | 2 | 2 | 1995 |
| Southwest Oncology Group | Academic/Hospital | 2 | 1 | 2 | 1995 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 0 | 2 | 2012 |
| University of California, Berkeley | Academic/Hospital | 2 | 2 | 1 | 2005 |
| Ben Gurion University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 1995 |
| Cancer Therapeutics Research Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| CerRx, Inc. | For profit | 1 | 1 | 1 | 2016 |
| EVAN Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 1995 |
| McGill University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| NantWorks | For profit | 1 | 1 | 1 | 2006 |
38 organizations
Page 1 / 2